The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling
Open accessAbstract
CpG oligodeoxynucleotides (CpG-ODNs) stimulate innate and adaptive immunity by binding to TLR9 molecules. Paradoxically, expression of the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is induced following i.v. CpG-ODN administration to mice. CpG-ODNs induced selective IDO expression by a minor population of splenic CD19+ dendritic cells (DCs) that did not express the plasmacytoid DC marker 120G8. Following CpG-ODN treatment, CD19+ DCs acquired potent IDO-dependent T cell suppressive functions. Signaling through IFN type I receptors was essential for IDO up-regulation, and CpG-ODNs induced selective activation of STAT-1 in CD19+ DCs. Thus, CpG-ODNs delivered systemically at relatively high doses elicited potent T cell regulatory responses by acting on a discrete, minor population of splenic DCs. The ability of CpG-ODNs to induce both stimulatory and regulatory responses offers novel opportunities for using them as immunomodulatory reagents but may complicate therapeutic use of CpG-ODNs to stimulate antitumor immunity in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 9×
“Thus, splenic CD19 DCs are specialized to respond to IFN- induced after TLR9 and B7 ligation by acquiring potent IDO-dependent T cell regulatory functions.”
BackgroundInfluentialCpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Self-citationMouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022
Immunotherapeutic uses of CpG oligodeoxynucleotides
Klinman, D. M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1329 · Cited by 1,012
Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction
Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C., & Taniguchi, T. (2005) · Nature · doi:10.1038/nature03547 · Cited by 912
Tolerance, DCs and tryptophan: much ado about IDO
Grohmann, U. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00072-3 · Cited by 766
Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P. A., Iwashima, M., & Munn, D. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1652 · Cited by 455
Self-citationAsselin-Paturel, C., Brizard, G., Pin, J.-J., Brière, F., & Trinchieri, G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6466 · Cited by 360
Cited by
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Self-citationTolerogenic dendritic cells and the quest for transplant tolerance
Morelli, A. E., & Thomson, A. W. (2007) · Nature Reviews Immunology · doi:10.1038/nri2132 · Cited by 899
Nguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
Hou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Self-citationImmunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Vollmer, J., & Krieg, A. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.12.008 · Cited by 585
Tryptophan metabolism, from nutrition to potential therapeutic applications
Le Floc’h, N., Otten, W., & Merlot, E. (2011) · Amino Acids · doi:10.1007/s00726-010-0752-7 · Cited by 561
IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
Baban, B., Chandler, P. R., Sharma, M. D., Pihkala, J., Koni, P. A., Munn, D. H., & Mellor, A. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900986 · Cited by 499
Self-citationIndoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 482
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation
Puccetti, P., & Grohmann, U. (2007) · Nature Reviews Immunology · doi:10.1038/nri2163 · Cited by 453
Chen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5396 · Cited by 453
Self-citationIDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 437
TLR-Activated B Cells Suppress T Cell-Mediated Autoimmunity
Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Gómez, E. C., Sweenie, C. H., Hao, Y., Freitas, A. A., Steinhoff, U., Anderton, S. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4763 · Cited by 436
“IF N - γ (n g/ m l) MOG(35-55) (μg/ml) 0 20 30 40 10 0 20 40 50”
BackgroundMethodInfluentialDevelopment of TLR9 agonists for cancer therapy
Krieg, A. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31414 · Cited by 429
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Lech, M., & Anders, H.-J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.001 · Cited by 418
The ‘microflora hypothesis’ of allergic diseases
Noverr, M. C., & Huffnagle, G. B. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02379.x · Cited by 394
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L.-A., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 392
TLR signaling by tumor and immune cells: a double-edged sword
Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210904 · Cited by 377
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Mbongue, J., Nicholas, D., Torrez, T., Kim, N.-S., Firek, A., & Langridge, W. (2015) · Vaccines · doi:10.3390/vaccines3030703 · Cited by 351
“Signaling through IFN type I receptors was essential for IDO upregulation, and CpG-ODNs induced selective activation of STAT-1 in CD19 DCs [68].”
BackgroundToll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity
Krieg, A. M., & Vollmer, J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00572.x · Cited by 350
Creating immune privilege: active local suppression that benefits friends, but protects foes
Mellor, A. L., & Munn, D. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2233 · Cited by 327
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 322
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy
Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C., Orabona, C., Belladonna, M. L., Ayroldi, E., Nocentini, G., et al. (2007) · Nature Medicine · doi:10.1038/nm1563 · Cited by 318
Regulatory B Cells Limit CNS Inflammation and Neurologic Deficits in Murine Experimental Stroke
Ren, X., Akiyoshi, K., Dziennis, S., Vandenbark, A. A., Herson, P. S., Hurn, P. D., & Offner, H. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1623-11.2011 · Cited by 300
Not always the bad guys: B cells as regulators of autoimmune pathology
Fillatreau, S., Gray, D., & Anderton, S. M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2315 · Cited by 295
Boasso, A., Herbeuval, J.-P., Hardy, A. W., Anderson, S. A., Dolan, M. J., Fuchs, D., & Shearer, G. M. (2007) · Blood · doi:10.1182/blood-2006-07-034785 · Cited by 288
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0106-z · Cited by 274
Self-citationTargeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Baird, J. R., Friedman, D., Cottam, B., Dubensky, T. W., Kanne, D. B., Bambina, S., Bahjat, K., Crittenden, M. R., & Gough, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3619 · Cited by 257
Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution
Sukka, S. R., Ampomah, P. B., Darville, L. N. F., Ngai, D., Wang, X., Kuriakose, G., Xiao, Y., Shi, J., Koomen, J. M., McCusker, R. H., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01115-7 · Cited by 82
Metadata
- Authors
- Mellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., & Munn, D. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-01
- Volume
- 175
- Issue
- 9
- Pages
- 5601-5605
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2105117087
- Cited by
- 290
- References
- 19
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.